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Background: Detailed knowledge of the essential pro-angiogenic biomolecules, the vascular endothelial growth
factor (VEGF) family and its receptors, in the characteristically heterogeneous tumor tissue is a pre-requisite for an
effective personalized target therapy. The effects of VEGF receptors after ligand binding are mediated through
receptor tyrosine autophosphorylation. We determined the relevance of the VEGFR-1 activating pathway for colon
cancer (CC) metastasis.
Methods: The expression profiles of VEGFR-1, phosphorylated (activated) VEGFR-1 (pVEGFR-1Tyr1048, pVEGFR-1Tyr1213
and pVEGFR-1Tyr1333) and the VEGFR-1 ligands (VEGF, PlGF and VEGF-B) were investigated using immunohistochemistry
in different tumor compartments (intratumoral - invasive front - extratumoral), cell types (tumor cells – macro-
(large and small vessels) and the microvasculature (capillaries) - inflammatory cells) in human sporadic non-metastatic,
lymphogenous metastatic and haematogenous metastatic CC.
Results: VEGF and PlGF produced by tumor cells have an autocrine affinity for their receptor VEGFR-1. Subsequent
PlGF-mediated receptor activation by autophosphorylation at Tyr1048 and Tyr1213 is a potential signaling pathway,
which in turn seems to protect against distant metastasis and, in regions of tumor budding, additionally against
lymph node metastasis. This autocrine link could be supported by possible formation of PlGF-VEGF heterodimers
and PlGF-PlGF homodimers, which are known to have anti-metastatic properties. In contrast, in order to enhance
their potential for distant metastasis tumor cells produce paracrine-acting VEGF-B. VEGFR-1 activation in tumor-
associated macrovasculature but not capillaries appears to affect metastatic ability. Paracrine-mediated receptor
autophosphorylation at Tyr1048 and Tyr1213 in small vessels located intratumorally and along the invasive front
appears to be inversely correlated with metastasis, especially distant metastasis. Additionally, macrovessels are
able to produce VEGFR-1 ligands, which influence the metastatic potential. Paracrine-acting VEGF-B production
by intratumorally located small vessels and autocrine-acting PlGF production by extratumorally located small
vessels seem to be associated with the non-metastatic phenotype. In contrast, VEGF-B-expressing extratumoral
large and small vessels correlate with distant metastasis. Lymphocyte-associated VEGFR-1 expression in the
invasive front without accompanying autophosphorylation could prevent against distant metastasis possibly by
acting as a decoy and scavenger receptor.
Conclusion: VEGFR-1 and its ligands participate in vascular, tumor cell-mediated and immuno-inflammatory
processes in a complex biomolecule-dependent and tumor zone-specific manner and hence could influence
metastatic behavior in CC.
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Angiogenesis is a hallmark of cancer and is essential for
tumor spread and life-threatening metastasis [1]. The
major mediators of tumor angiogenesis are the vascular
endothelial growth factor (VEGF) family and its recep-
tors [2]. The use of VEGF pathway inhibitors to impair
angiogenesis represents a clinically validated therapeutic
strategy. However, such treatments are not completely
curative, and a large number of tumors develop resist-
ance or show recurrence after a progression-free period
[3]. Contributory limiting factors for complete thera-
peutic success are the tumor heterogeneity and the com-
plex cross-talk between tumor cells and the tumor
microenvironment, which principally involves the tumor-
associated vasculature and the peritumoral inflammatory
reaction. A systematic analysis of the expression patterns
of the ligands and receptors of the VEGF family in the
tumor cells and the components of the tumor microenvir-
onment in situ could contribute to a better understanding
of the underlying interactive mechanisms determining
tumor progressive behavior and subsequently help to im-
prove the therapeutic approaches. In this context, the
present study focusses on the expression profiles of mem-
bers of the VEGF receptor-1 (VEGFR-1) activating path-
way in colon cancer (CC) tissue.
VEGFR-1 is a member of the receptor tyrosine kinase
(RTK) gene family and acts as a high affinity receptor
for VEGF (often referred to as VEGF without a suffix),
placenta growth factor (PlGF), and VEGF-B [4,5].
VEGFR-1 is composed of seven extracellular immuno-
globulin homology domains, a single transmembrane re-
gion and an intracellular tyrosine kinase domain split by
a kinase insert that is important for substrate recogni-
tion. It was originally identified by its important role in
angiogenic processes. Further studies have demonstrated
that the VEGFR-1 signaling pathway is also crucial for
tumor growth, progression and metastasis. The mechan-
ism by which the activation of VEGFR1 elicits these cel-
lular events is not yet clearly understood. However, it is
known that tyrosine autophosphorylation represents a
crucial event in the activation of RTKs [6]. RTK activation
is associated with ligand-mediated receptor dimerization,
transphosphorylation and docking of signaling proteins to
receptor phosphotyrosines. Residues of the C-terminal tail,
including tyrosines (Tyr)1213 and 1333 and residues
within the tyrosine kinase domain such as Tyr1048, have
been identified as phosphorylation sites of VEGFR-1 [7,8].
Notably, in tumors there is also a possible oncogenic
RTK activation by mutations and abnormally stimu-
lated autocrine-paracrine loops [9]. These activation
loops are stimulated when a RTK is abnormally
expressed or overexpressed in the presence of its asso-
ciated ligand or when there is an overexpression of the
ligand in the presence of its cognate receptor. In situdata on the phosphorylated, activated status of VEGFR-
1 in human tumor tissue are not available. Recently,
specific antibodies for paraffin-embedded sections have
been produced which detect endogenous levels of
VEGFR-1 only when phosphorylated at the appropriate
tyrosine residue. This offers the morphologist the pos-
sibility to localize those cells in a heterogeneous popu-
lation which possess this functional phenotype.
The role of the most widely studied angiogenic factor,
VEGF, in tumor angiogenesis via stimulation of VEGFRs
expressed on tumor endothelium is well established
[10,11]. VEGF stimulation activates endothelial prolifera-
tion, migration, survival and vascular permeability. Add-
itionally, the hypothesis has been formulated that VEGF
supports tumor growth and progression by acting dir-
ectly through VEGFRs expressed on tumor cells. How-
ever, the significance of autocrine or paracrine acting
VEGF in neoplastic tissue for tumor behavior is not fully
elucidated.
PlGF is the second member of the VEGF family dis-
covered and is highly expressed in the placenta through-
out all stages of gestation [12,13]. PlGF binds exclusively
to the VEGFR-1 with high affinity compared to VEGF
and to VEGF-B. Moreover, if PlGF and VEGF are co-
expressed in the same cell, they may generate PlGF/PlGF
and VEGF/VEGF homodimers as well as PlGF/VEGF
heterodimers. Each of these ligand pairs is able to bind
and activate VEGFR-1, but receptor stimulation may
lead to varying cellular responses. PlGF is produced by
tumor cells, endothelial cells and other cells of the
tumor stroma, including inflammatory cells. Although it
is known that PlGF can stimulate tumor angiogenesis,
until now the role of PlGF in tumor progression remains
controversial.
VEGF-B, another ligand of VEGFR-1, seems to be a re-
dundant and elusive member of the VEGF family [14].
Except for its ischemia-associated, myocardium-specific
angiogenic activity, VEGF-B is minimally involved in
angiogenesis in other organs. On the other hand, VEGF-
B is a critical regulator of energy metabolism by regulat-
ing fatty acid uptake. Moreover, VEGF-B plays an
important role in cell survival of vascular and non-
vascular cells. Interestingly, VEGF-B is expressed in vir-
tually all malignant tumor types, but its role in tumor
biology appears limited [15].
In order to determine the relevance of the VEGFR-1
activating pathway for CC metastasis we investigated the
expression profiles of the total and phosphorylated form
of this receptor and its ligands in tumor cells, tumor-
associated macro- (large and small vessels) and micro-
vasculature (capillaries) and peritumoral inflammatory
cells in 86 non-metastatic (N0/M0), lymphogenous (N+)
and haematogenous (M+) metastatic, locally advanced
CC. Taking tumor heterogeneity into consideration, the
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gated, strategically important compartments, namely
tumor center (zone 1), invasive margin (zone 2) and
tumor-free surrounding adipose cell-rich soft tissue
(zone 3). Regarding the tumoral expression pattern we
focused our attention on the topological staining distri-
bution, especially on differences in staining intensity be-
tween the central tumor fraction and the invasive tumor
margin. The expression patterns were assessed holistically
in the light of previously published data about relevant
features of CC such as tumor budding, tumor necrosis,
peritumoral inflammation and vascular density [16].
Methods
Ethics statement
Ethical approval was granted by the Clinical Research
Ethics Commitee of the federal state of Rhineland-
Palatinate (Mainz, Germany). Written informed consent
was obtained from all patients.
Tissue samples
The CC tissue samples used in this study derived from
86 patients with an average age of 65.2 (range 52–83)
undergoing elective surgery for sporadic (non-hereditary)
CC at the University of Mainz during the years 1998–
2003. Familial adenomatous polyposis (FAP), hereditary
nonpolyposis colorectal cancer (HNPCC) and carcinomas
associated with ulcerative colitis or Crohn’s Disease were
exclusion criteria. All tumors were staged following the
guidelines of the TNM Classification of Malignant Tu-
mors. With respect to the T status all tumors investigated
were T3 (infiltration of subserosa) and moderately differ-
entiated (G2). According to metastatic status 37 of them
were non-metastatic, 24 lymphogenous metastatic and 25
haematogenous metastatic CC at the time of diagnosis.
Immunohistochemistry
All immunohistochemical reactions were conducted on
formalin-fixed and paraffin-embedded samples.
VEGF-B, PlGF and pVEGFR-1Tyr1333: After deparaffi-
nation heat-induced epitope retrieval was performed in
Tris-EDTA buffer pH 9,0 for 20 min. using a vegetable
steamer. Non-specific binding was blocked by Dako
REAL™ Peroxidase-Blocking Solution (Dako, Hamburg,
Germany) prior to incubation with the primary antibody.
For the immunohistochemical staining procedure DAKO
REAL™EnVision™Detection System, Peroxidase/DAB+,
Rabbit/Mouse was utilized following the manufacturer’s
instructions. The primary antibodies, mouse monoclonal
anti-VEGF-B (Santa Cruz Biotechnology, Inc., Santa
Cruz, USA) and rabbit polyclonal anti-phosphoVEGFR-1
(pTyr1333; Abcam, Cambridge, UK) were applied at a
dilution of 1:50 and 1:100 respectively for 1 h at room
temperature. The primary antibody rabbit polyclonalanti-PlGF (Abcam) was applied at a dilution of 1:50 over
night at 4°C.
VEGF,VEGFR-1, pVEGFR-1Tyr1048 and pVEGFR-1Tyr1213:
After deparaffination endogenous peroxidase activity
was blocked with hydrogen peroxide. Heat-induced epi-
tope retrieval was performed in citrate buffer pH 6,0
for 8 min. using a pressure cooker. The detection kits
ZytoChem Plus HRP Kit, anti-Rabbit and ZytoChem
Plus (HRP) Polymer Kit, anti-Mouse (Zytomed Systems,
Berlin, Germany) were utilized following the manufac-
turer’s instructions. The primary antibodies were applied
for 45 min. at room temperature and diluted as follows:
mouse monoclonal anti-VEGF (Abcam) 1:40, rabbit
monoclonal anti-VEGFR-1 (Y103, Abcam) 1:100, rabbit
polyclonal anti-phosphoVEGFR-1 (pY1048, Abcam), 1:90
and rabbit polyclonal Anti-phosphoVEGFR-1 (pY1213,
Ab-2, Merck, Darmstadt, Germany) 1:1000. Staining was
completed with Novolink Max DAB (Polymer) Kit (Leica
Biosystems, Wetzlar, Germany).
Sections were counterstained with Mayer's hematoxylin
(Thermo Fisher Scientific, Fremont, USA). To prove the
specificity of the immunoreactions, CC samples were
stained solely with the secondary antibody, omitting the
primary antibody, and these served as negative control.
Immunostaining reactions of each sample were evalu-
ated independently by two authors (CJ and NS) without
knowledge of the metastatic status. The endothelial
and inflammatory cell staining was judged as either
negative or positive. The intensity of the tumoral stain-
ing was scored on a semiquantitative scale from 0 to 2
depending on the investigated biomolecule (0: no
staining, 1: weak staining, 2: strong staining). In most
cases the staining was homogeneous. In those cases
where heterogeneous staining was observed, that level
of staining intensity which was visible in more than
50% of the cells was chosen for the classification into a
defined group. In those cases (<5%) in which the evalu-
ation results of the two independent authors (CJ and NS)
were different, the specimens were re-evaluated together
and a consistent score was found.Histopathological analysis
Tumor budding was defined as disseminated single tumor
cells and oligocellular tumor clusters (≤5 tumor cells) at
the invasive margin.
Capillaries (microvessels) were vessels with clearly de-
fined lumina or linear vessel shape lacking a definable
smooth muscle wall.
Small vessels (macrovessels) were vessels with narrow
lumina and up to five well definable smooth muscle
layers.
Large vessels (macrovessels) were arteries with a thick
muscular wall.
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Statistical significance was assessed using Fisher's exact
test. p < 0.05 was considered to be statistically significant.
The correlations between expression of VEGFR-1 and li-
gands were assessed with the Spearman’s rank test.
Results
Tumor cell- associated VEGFR-1 activation in CC tissue
The VEGFR-1 ligands VEGF, PlGF and VEGF-B were
expressed in the cytoplasm of tumor cells by 82%, 83%
and 26% of the CC, respectively (Table 1). In most of the
tumors VEGF was detected with uniform staining inten-
sity and distribution within the three comparative tumor
fractions. PlGF overexpression and VEGF-B absence
each correlated significantly with non-metastatic status
in comparison to distant metastatic spread (p = 0.04 and
p = 0.02, respectively). However, it is worth mentioning
that the percentage distribution between negative and
positive PlGF expression was approximately of the same
order in the non-metastatic and metastatic groups (no
statistical significance). Correlation analysis displayed
existing moderate VEGF/VEGFR-1 and weak PlGF/
VEGFR-1 ligand-receptor affinity (r = 0.5, p = 0.0001 as
well as r = 0.3, p = 0.007 in tumor center and r = 0.3 andTable 1 Percentage distribution of the VEGFR-1 ligands in tum
Score N0/M0 (%) N+ (%) N0/M
Tumor center
VEGF 0 14 25
1 68 54
2 18 21
PlGF 0 14 21
1 48 54
2 38 25




VEGF 0 14 15
1 72 60
2 14 25
PlGF 0 11 18
1 50 46
2 39 36
VEGF-B 0 75 80
1 14 15
2 11 5
The intensity of the tumoral staining was scored on a semiquantitative scale from 0 to
staining). For the statistical analysis using Fisher’s exact test the examined cases were s
VEGF and VEGF-B or negative, low/high expression for PlGF. The line in the score (sta
The line in the column “CC %” indicates the percentage distribution of colon carc
was taken as statistically significant. NS, not significant.p = 0.02 in tumor budding, respectively; Table 2). The
documented PlGF/VEGFR-1 affinity was observed exclu-
sively in the metastatic cases. It is known, that if PlGF
and VEGF are co-expressed in the same cell, they may
generate PlGF/PlGF and VEGF/VEGF homodimers as
well as PlGF/VEGF heterodimers [13]. Each of these lig-
and formations is able to bind and activate VEGFR-1 but
receptor stimulation may lead to different cellular re-
sponses. The percentage distribution of PlGF/VEGF di-
mers within the various CC groups was approximately
the same, without statistical significance (Table 3).
In a next step we investigated the VEGFR-1 ligand ex-
pression profiles in the tumor budding regions, which
reflect the spreading capacity of tumor cells. Here, the
percentage distribution of cases with positive VEGFR-1
ligand immunoreactivity was similar to the tumor center,
namely 85% for VEGF and PlGF and 30% for VEGF-B
(Table 1). Consequently, the correlations among the
metastatic categories remained constant, except for
VEGF-B with a difference in the expression pattern be-
tween N0/M0 and M+ CC just below the level of statis-
tical significance (p = 0.06).
In the tumor center and tumor budding regions 87%
and 94% of the CC, respectively, have shown a positiveor cells of CC tissue
0 vs. N + p M+ (%) N0/M0 vs. M + p CC (%)
NS 0.3 16 NS 1.0 18
60 82
24
NS 0.5 16 0.04 17
72 83
12
NS 1.0 56 0.02 74
44 26
0
NS 1.0 17 NS 1.0 15
58 85
25
NS 1.0 16 0.03 15
72 85
12
NS 1.0 56 NS 0.06 70
36 30
8
2 for the investigated biomolecule (0: no staining, 1: weak staining, 2: strong
eparated into two groups characterized by a negative/positive expression for
ining intensity) column indicates this dichotomization for each biomolecule.
inomas with negative and positive expression of each biomolecule. p < 0.05
Table 2 Numerical distribution of ligand/VEGFR-1 correlations in tumor cells of CC tissue
VEGFR-1 VEGF p PlGF p VEGF-B p
+ - (r) + - (r) + - (r)
Tumor center
CC + 68 8 0.0001 66 10 0.007 23 56 NS 0.4
- 3 7 (0.5) 4 5 (0.3) 1 6 (0.1)
N0/M0 + 32 4 0.009 31 5 NS 0.7 6 30 NS 0.7
- 0 1 (0.4) 1 0 (0.07) 0 1 (0.07)
N+ + 16 3 0.04 17 3 0.009 7 15 NS 0.4
- 2 3 (0.4) 1 3 (0.5) 0 2 (0.1)
M+ + 20 1 0.0001 18 2 0.04 10 11 NS 0.6
- 1 3 (0.7) 2 2 (0.4) 1 3 (0.1)
Tumor budding
CC + 59 10 NS 0.4 60 7 0.02 21 47 NS 0.6
- 2 1 (0.01) 2 3 (0. 4) 1 4 (0.05)
N0/M0 + 24 3 0.01 24 3 NS 0.7 7 20 NS 0.6
- 0 1 (0.5) 1 0 (0.09) 0 1 (0.1)
N+ + 16 3 NS 0.7 17 2 0.01 4 15 NS 0.6
- 1 0 (0.1) 0 1 (0.5) 0 1 (0.1)
M+ + 19 4 NS 0.7 19 2 0.01 10 12 NS 0.7
- 1 0 (0.1) 1 2 (0.5) 1 2 (0.07)
Positive tumoral expression of VEGFR-1 is positively correlated with positive tumoral VEGF expression in the tumor center and positive tumoral PlGF expression in
the tumor center and tumor budding regions. r = Spearman’s rank correlation coefficient. p < 0.05 was taken as statistically significant. NS, not significant.
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VEGFR-1 expression in the tumor core was associated
with lymphogenous metastasis (p = 0.03). From the 37
investigated N0/M0 cases 27 CC exhibited tumor bud-
ding. Interestingly, from the 10 cases without this
histopathological feature, 9 tumors were characterized
by positive VEGFR-1 expression. Consequently, in the
tumor budding regions significant differences did not
exist between non-metastatic and metastatic status.
The VEGFR-1 phosphorylated at Tyr1048 and Ty1213
exhibited a submembranous accentuated cytoplasmatic
and at Tyr1333 a specific nuclear immunoreactivity
(Figure1A-C). Positive pVEGFR-1Tyr1048, pVEGFR-
1Tyr1213 and pVEGFR-1Tyr1333 expression was seen in
74%, 64% and 55%, respectively (Table 4). Negative
pVEGFR-1Tyr1048 and pVEGFR-1Tyr1213 immunoreactiv-
ity was significantly correlated with distant metastatic
stage (p = 0.01). In the tumor budding regions the per-
centage distribution of positive pVEGFR-1 expressionTable 3 Percentage distribution of potential autocrine
PlGF/VEGF dimer formation in tumor cells of CC tissue
N0/M0 (%) N+ (%) p M+ (%) p
PlGF/VEGF 75 63 NS 0.4 74 NS 0.8
PlGF/PlGF 14 25 NS 0.3 13 NS 1.0
VEGF/VEGF 11 12 NS 1.0 13 NS 1.0in the same sequence as above was 71%, 64% and 47%, re-
spectively, and thus almost identical (Table 4, Figure 1D).
From the 4 N+ CC without the presence of tumor bud-
ding 3 expressed strong immunostaining levels. This led
to an additional statistical significance for pVEGFR-
1Tyr1048 in tumor budding regions between N0/M0 and
N+ CC (p = 0.01). pVEGFR-1Tyr1333 immunoreactivity
had similar immunointensity distribution throughout
all comparative groups.
Since a concomitant VEGFR-1/pVEGFR-1 immunopo-
sitivity can be interpreted as a potentially ligand-
dependent tyrosine autophosphorylation, co-expression
profiles were also analyzed. These analyses revealed the
same significant correlations as described above, but
with an additional significance concerning the associ-
ation between negative VEGFR-1/pVEGFR-1Tyr1213 and
N+ CC in the presence of tumor budding (p = 0.02,
Table 5).
Inflammatory cell-associated VEGFR-1 activation in CC
tissue
Of the three VEGFR-1 ligands only PlGF was markedly
expressed on inflammatory cells – independent of the
tumor zone – on average in 80% of the cases (Table 6).
VEGF expression was sporadic and occurred in less than
10% of all cases. None of the CC showed VEGF-B
immunopositivity. VEGFR-1 and pVEGFR-1 revealed
Table 4 Percentage distribution of VEGFR-1 and pVEGFR-1 in tumor cells of CC tissue
Score N0/M0 (%) N+ (%) N0/M0 vs. N + p M+ (%) N0/M0 vs. M + p CC (%)
Tumor center
VEGFR-1 0 3 21 0.03 16 NS 0.1 13
1 11 21 12 87
2 86 58 72
pVEGFR-1Tyr1048 0 11 29 NS 0.09 30 0.01 26
741 59 54 44
2 30 17 16
pVEGFR-1Tyr1213 0 19 38 NS 0.1 52 0.01 36
641 64 46 32
2 17 16 16
pVEGFR-1Tyr1333 0 38 46 NS 0.8 52 NS 0.3 45
551 49 33 44
2 13 21 4
Tumor budding
VEGFR-1 0 0 5 NS 0.4 12 NS 0.1 6
941 15 15 12
2 85 80 76
pVEGFR-1Tyr1048 0 4 30 0.01 40 0.003 29
711 66 50 44
2 30 20 16
pVEGFR-1Tyr1213 0 19 38 NS 0.2 52 0.01 36
641 64 46 32
2 17 16 16
pVEGFR-1Tyr1333 0 46 50 NS 1.0 64 NS 0.3 53
471 43 25 32
2 11 25 4
The intensity of the tumoral staining was scored on a semiquantitative scale from 0 to 2 for the investigated biomolecule (0: no staining, 1: weak staining,
2: strong staining). For the statistical analysis using Fisher´s exact test the examined cases were separated into two groups characterized by a negative/positive
expression. The line in the staining intensity column indicates this dichotomization for each biomolecule. The line in the column “CC %” indicates the percentage
distribution of colon carcinomas with negative and positive expression of each biomolecule. p < 0.05 was taken as statistically significant. NS, not significant.
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33% to 83% intratumorally and from 50% to 95% along
the invasive front. The only significant difference was
observed in the tumor border, where in 92% of the non-
metastatic CC inflammatory cells were VEGFR-1 positive
whereas only 68% of the cases with distant metastasis
had a positive immunoreaction (p = 0.02, Figure 1E). Based
on correlation analysis no significance between PlGF and
VEGFR-1 could be demonstrated (data not shown).
Vasculature-associated VEGFR-1 activation in CC tissue
The vascular expression profiles of the VEGFR-1 activat-
ing pathway were investigated separately in the three
vessel types (large vessels, small vessels and capillaries)
within the three zones.
Concerning VEGF, there were markedly more cases
with VEGF-expressing macro- and microvascular vessels(N0/M0, M+) at the invasive front compared to the
tumor center (Figure 2). In nodal-positive CC (N+) this
expression was observed only in the macrovasculature.
In comparison with lymph node metastatic CC almost
twice as many non-metastatic carcinomas displayed
positive VEGF staining of the microvascular vessels in
zone 2 (p = 0.02). Intratumoral capillaries within the des-
moplastic stroma showed predominantly compressed lu-
mina, although some were partly open (Figure 3A1,2).
In contrast, a clear dominance of capillaries with open
lumina could be seen in zone 3.
In more than two-thirds of the cases a positive endo-
thelial PlGF reaction was seen in both large and small
vessels, as well as in capillaries (Figure 2). However, no
significant differences could be established with respect
to the metastatic status. In addition to PlGF-positive ath-
erosclerotic large vessels, altered blood vessels with
Figure 1 Immunohistochemical staining of pVEGFR-1 in tumor cells and VEGFR-1 in inflammatory cells of CC tissue. (A) Characteristic
pVEGFR-1Tyr1048 expression in tumor cells with membranous and cytoplasmic immunostaining (x 400). (B) Characteristic pVEGFR-1Tyr1213 expression
in tumor cells with membranous and cytoplasmic immunostaining (x 400). (C) Characteristic pVEGFR-1Tyr1333 expression in tumor cells with
nuclear immunostaining (x 400). (D) pVEGFR-1 expression in tumor cells in tumor budding regions. Tumor budding was defined as single
tumor cells and oligocellular tumor cell clusters along the invasive margin (D1, H.E., x 200). Expression of pVEGFR-1Tyr1048 (D2, x 200) and
pVEGFR-1Tyr1213 (D3, x 200) in tumor budding regions. (E) Characteristic VEGFR-1 expression in inflammatory cells. Lymph follicles along the
invasive front (E1, H.E., x 40) with VEGFR-1 immunopositivity (E2, x 100) in a non-metastatic CC case.
Table 5 Numerical and percentage distribution of VEGFR-1/pVEGFR-1 co-expression tumor cells
N0/M0 n (%) N+ n (%) N0/M0 vs. N + p M+ n (%) N0/M0 vs. M + p
Co-expression in the tumor center
VEGFR-1+/pVEGFR-1Tyr1048+ 36/32 (89) 19/13 (68) NS 0.08 21/13 (62) 0.02
VEGFR-1+/pVEGFR-1Tyr1213+ 36/28 (78) 19/12 (63) NS 0.3 21/10 (48) 0.02
VEGFR-1+/pVEGFR-1Tyr1333+ 36/22 (61) 19/9 (47) NS 0.4 21/10 (48) NS 0.4
Co-expression in tumor budding regions
VEGFR-1+/pVEGFR-1Tyr1048 + 26/25 (96) 19/13 (68) 0.02 22/14 (64) 0.005
VEGFR-1+/pVEGFR-1Tyr1213 + 26/21 (81) 19/9 (47) 0.02 22/11 (50) 0.01
VEGFR-1+/pVEGFR-1Tyr1333 + 26/13 (50) 19/9 (47) NS 1.0 22/9 (41) NS 0.6
n: total number of VEGFR-1 positive cases/total number of pVEGFR-1 positive cases with concomitant VEGFR-1 positivity. p < 0.05 statistically significant,
NS not significant.
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Table 6 Percentage distribution of the VEGFR-1 ligands, VEGFR-1 and pVEGFR-1 in inflammatory cells of CC tissue
N0/M0 (%) N+ (%) M+ (%)
z1 z2 z1 N0/M0 vs. N + p z2 N0/M0 vs. N + p z1 N0/M0 vs. M + p z2 N0/M0 vs. M + p
VEGF 3 5 5 NS 1.0 18 NS 0.2 5 NS 1.0 8 NS 1.0
PlGF 69 84 78 NS 0.7 95 NS 0.2 71 NS 1.0 79 NS 0.7
VEGF-B 0 0 0 0 0 0
VEGFR-1 67 92 50 NS 0.2 82 NS 0.4 59 NS 0.6 68 0.02
pVEGFR-1Tyr1048 83 95 68 NS 0.3 91 NS 0.6 68 NS 0.2 80 NS 0.1
pVEGFR-1Tyr1213 60 64 33 NS 0.1 50 NS 1.0 50 NS 0.6 56 NS 0.8
pVEGFR-1Tyr1333 75 86 67 NS 0.5 68 NS 0.1 72 NS 1.0 68 NS 0.1
z1 = zone 1, z2 = zone 2. p < 0.05 statistically significant. NS, not significant.
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also present (Figure 3B1-4). These immature vessels
were in almost all cases PlGF-positive.
Staining of VEGF-B was seen in the macrovasculature,
but, with exception of single tumor cases, not in the mi-
crovasculature (Figures 2 and 3C1,2). Making a com-
parison between cases without metastases (N0/M0) and
distant metastases (M+) on the one hand and cases with
lymph node metastases (N+) on the other hand showedFigure 2 Graphical presentation of percentage distribution of the VEGtwo distinguishing features. In nodal metastatic CC there
were significantly less cases with VEGF-B positive small
vessels in the tumor center (p = 0.007 for N0/M0 vs. N+
and p = 0.02 for N+ vs. M+). In the distant metastasizing
CC significantly more cases revealed VEGF-B-positive
small vessels (p = 0.04 for N0/M0 vs. M+ and p = 0.003
for N+ vs. M+) and large vessels (p = 0.03 for N0/M0 vs.
M+ and p = 0.008 for N+ vs. M+) in the extratumoral
adipose tissue (Figure 2).FR-1 ligands in the vasculature of CC tissue.
Figure 3 (See legend on next page.)
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Figure 3 Immunohistochemical staining of the VEGFR-1 ligands and pVEGFR-1 in the vasculature of CC tissue. (A) Characteristic endothelial
VEGF expression. VEGF positive intratumoral microvascular vessels with predominantly compressed lumina (A1, x 100) and extratumoral microvascular
vessels with open lumina (A2, x 100). (B) Characteristic endothelial PlGF expression: Macrovascular vessels with arteriosclerotic changes (B1, H.E., x 40)
and PlGF immunopositivity (B2, x 40) as well as altered macrovascular vessels with discontinuous, hypoplastic smooth muscle cell layer (B3, H.E., x 40)
and PlGF immunopositivity (B4, x 40). (C) Characteristic endothelial VEGF-B expression: Small and large vessels with VEGF-B immunopositivity (C1, x 100)
and capillaries with absent VEGF-B expression (C2, x100). (D) Characteristic endothelial pVEGFR-1Tyr1048 expression in small intratumoral vessels (x 100).
(E) Characteristic endothelial pVEGFR-1Tyr1213 expression in small intratumoral vessels (x 100).
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segments of the vascular network was observed with a
moderate increase of cases with VEGFR-1-positive capil-
laries and small vessels from zone 1 to zone 2 (Figure 4).
No significant correlation between non-metastatic and
metastatic status was noted.
The three zones exhibited endothelial expression of
pVEGFR-1Tyr1048 in all segments of the vascular sys-
tem (Figures 3D, 4). In comparison with N0/M0 car-
cinomas only a small number of M + −cases presented
phosphorylated receptor-positive small vessels in the
tumor center (p = 0.03).
Endothelial expression of pVEGFR-1Tyr1213 was detect-
able in the macrovasculature in all three zones (Figures 3EFigure 4 Graphical presentation of percentage distribution of VEGFR-and 4). Phosphorylated receptor-positive small vessels in
the tumor center were significantly more often de-
tected in non-metastatic cases (p = 0.03 N0/M0 vs. N+
and p = 0.002 N0/M0 vs. M+). Positive capillary
pVEGFR-1Tyr1213 immunoreactivity was present only
in a small number of cases.
Endothelial expression of pVEGFR-1Tyr1333 was ob-
served very infrequently in all vascular segments
(Figure 4).
Vascular ligand/VEGFR-1 correlation analysis revealed
that in zone 3 located PlGF-expressing capillaries and
small vessels were significantly correlated with their recep-
tor expression (r = 0.4, p = 0.0008 and r = 0.3, p = 0.01, re-
spectively, data not shown). PlGF-VEGFR-1 co-expression1 and pVEGFR-1 in the vasculature of CC tissue.
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in non-metastatic cases (84% in N0/M0 versus 61% in
N+ (p = 0.07) and 57% for M+ (p = 0.03)).
VEGFR-1/pVEGFR-1 co-expression analysis showed
statistical significance for small vessels but not for capil-
laries (Table 7). Small intratumoral vessels with com-
bined VEGFR-1/pVEGFR-1Tyr1048 expression occurred
significantly more often in non-metastatic CC compared
with lymphogenous and haematogenous metastatic cases
(p = 0.01 and p = 0.02, respectively). Furthermore,
metastasis-free CC revealed in a larger number of
cases a simultaneous positive VEGFR-1/pVEGFR-1Tyr1213
immunoreaction in small vessels in the tumor center and
along the invasive margin compared to distant-metastatic
cases (p = 0.05 and p = 0.04, respectively). As there was
only a small number of cases with co-expression in large
vessels, this vessel type was not considered for statistical
evaluation.
Figure 5 represents a summary of our results in sche-
matic form.
Discussion
This study investigated the tumor cell-, inflammatory
cell- and vasculature-associated expression of total and
phosphorylated VEGFR-1 and its ligands in different
compartments of colon cancer tissue in relation to the
metastatic status. The accentuated macrovascular VEGF-
expression in the extratumoral tissue emphasizes the
important role of the tumor-surrounding area for
VEGF-controlled blood vessel-related processes, which
are crucial to provide the tumor with an adequate sup-
ply of oxygen and nutrients. Additionally, the large
number of microvascular VEGF-expressing cases in theTable 7 Numerical and percentage distribution of VEGFR-1/pV
N0/M0 n (%) N+ n (%)
VEGFR1+/pVEGFR-1Tyr1048+
Capillaries zone 1 22/9 (41) 10/4 (40)
zone 2 28/11 (39) 13/8 (62)
zone 3 21/12 (57) 12/8 (67)
small vessels zone 1 23/19 (83) 11/4 (36)
zone 2 29/20 (69) 15/12 (80)
zone 3 27/22 (81) 14/13 (93)
VEGFR-1+/pVEGFR-1Tyr1213 +
Capillaries zone 1 21/6 (28) 8/2 (25)
zone 2 27/7 (26) 12/3 (25)
zone 3 27/16 (59) 14/5 (36)
small vessels zone 1 22/12 (55) 11/3 (27)
zone 2 28/13 (46) 16/8 (50)
zone 3 27/16 (59) 14/5 (36)
n: total number of VEGFR-1 positive cases/total number of pVEGFR-1 positive cases
NS not significant.extratumoral region in nodal metastatic CC underlines
the relevance of VEGF-controlled extratumoral micro-
vasculature for lymph node metastasis. Microvessels in
the immediate tumor vicinity with their open lumina
are probably the most favorable site of entry and fur-
ther transport of tumor cells compared to the mostly
collapsed intratumoral microvessels, reflecting a mech-
anical stress situation of the muscle-layer free vascula-
ture in desmoplastic tumor tissue. This topological
peculiarity of the microvasculature in CC was clearly
documented in the histological examination of the
tumor tissue. Tumor cells also expressed VEGF in
more than 75% of the CC, but without association with
the metastatic status. Lack of significant correlation be-
tween endothelial as well as epithelial VEGF expression
and CC metastasis in our study is in accordance with
the results of several research groups [17-20]. There
are, however, other reports describing a significant cor-
relation between VEGF expression and lymph node as
well as distant metastasis in CC [21,22]. In most publica-
tions, a detailed study of the cell type-related VEGF-
expression was omitted. In our opinion, precise evaluation
and characterization of the cell subtypes within the tumor
tissue showing VEGF-immunopositivity could contribute
to a better understanding of the paracrine and autocrine
functions of this factor for tumor progression. Although
the most potent angiogenic factor, VEGF expression in
microvascular endothelial cells was not associated with
metastatic status in our study, thus supporting previously
published data showing no correlation between micro-
vascular density (MVD) and metastatic stage in CC [16].
Since MVD analysis is the morphological gold standard to
assess angiogenesis in human tumors, these results clearlyEGFR-1 co-expression in the vasculature
N0/M0 vs. N + p M+ n (%) N0/M0 vs. M + p
NS 1.0 14/7 (50) NS 0.7
NS 0.3 19/13 (68) NS 0.08
NS 0.7 11/5 (45) NS 0.7
0.01 12/5 (42) 0.02
NS 0.5 17/14 (82) NS 0.5
NS 0.6 13/7 (54) NS 0.2
NS 1.0 14/2 (14) NS 0.4
NS 1.0 18/1 (6) NS 0.1
NS 0.2 13/7 (54) NS 1.0
NS 0.3 11/2 (18) 0.05
NS 1.0 16/2 (13) 0.04
NS 0.2 13/7 (54) NS 1.0
with concomitant VEGFR-1 positivity. p < 0.05 statistically significant,
Figure 5 Schematic presentation of VEGFR-1 activation in CC tissue and its association with metastasis. VEGF produced in the tumor
center and PlGF produced intratumorally and in tumor budding regions by tumor cells have an autocrine affinity for their receptor VEGFR-1.
Subsequent PlGF-mediated receptor activation by autophosphorylation at Tyr1048 and Tyr1213 is a potential signaling pathway, which in turn
seems to inhibit distant metastasis and, in regions of tumor budding, additionally lymph node metastasis. This autocrine link could be supported
by possible formation of PlGF-VEGF heterodimers and PlGF-PlGF homodimers, which are known to have anti-metastatic properties. In contrast, in
order to enhance their potential for distant metastasis, tumor cells in the tumor center produce paracrine-acting VEGF-B. Inflammatory cell associated
VEGFR-1 expression in the invasive front (zone 2) without accompanying autophosphorylation could inhibit distant metastasis possibly by acting as a
decoy and scavenger receptor. In small vessels located intratumorally (zone 1) paracrine-mediated receptor autophosphorylation at Tyr1048 and
Tyr1213 and paracrine-acting VEGF-B production appear to be associated with a non-metastatic phenotype. In small vessels located along the invasive
front (zone 2) paracrine-mediated receptor autophosphorylation at Tyr1213 may cause inhibition of metastasis. Autocrine-acting PlGF production by
small vessels located extratumorally (zone 3) appears to be associated with a non-metastatic phenotype. In contrast, VEGF-B-expressing extratumoral
small vessels correlate with distant metastasis.
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metastasis in CC.
Recently, it has been shown that VEGF also exhibits
immunosuppressive properties by inducing the accumu-
lation of immature dendritic cells, myeloid-derived sup-
pressor cells, regulatory T cells and inhibition of T
lymphocyte migration to the tumor [23]. Data on VEGF
involvement in immuno-inflammatory responses in
colon tumor tissue are very rare. In one study VEGF-
overexpression was observed in lymphocytes along the
invasive tumor front of CC [18]. We found only a spor-
adic, non-specifically located inflammatory cell-associated
VEGF expression in the investigated CC cases. Furtherstudies with regard to the VEGF isoforms are required to
verify the immunomodulatory properties of this factor.
VEGF-B was not involved in the peritumoral inflamma-
tory response. In contrast, an abundant PlGF-expression
of inflammatory cells in the tumor center and especially
the marginal tumor portion was demonstrated without ef-
fects on metastatic behavior. VEGFR-1 expression in the
invasive front, especially in the non-metastatic cases
showed significant differences in comparison to the
distant-metastatic CC. Since a significant ligand/receptor
correlation was lacking, an autocrine PlGF/VEGFR-1
link as an appropriate metastasis-limiting tool can be
excluded. Likewise, pVEGFR-1 expression was not
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gether, lymphocyte-associated VEGFR-1 expression at
the tumor-host interface in almost all non-metastatic
CC underlines the possible importance of this receptor
for preventing distant metastasis. Apart from conceiv-
ably underlying immunomodulatory mechanisms, a
function as decoy and scavenger receptor for pro-
metastatic acting VEGFR-1 ligands from the tissue
vicinity might also be possible. In accordance with our
results, there are several reports indicating that
VEGFR-1 is expressed on different T cell subsets, sug-
gesting its potential importance in immunity [24,25].
In a conspicuously large number of non-metastatic
and metastatic cases all tumor zones displayed PlGF-
positive micro- and macrovasculature. In addition to its
already well documented angiogenic properties, these re-
sults provide evidence for an involvement of PlGF in the
tumor vascularization process. In this context, in in-
farcted myocardial tissue sufficient endothelial PlGF pro-
duction of autochthonous vessels within the necrotic
myocardium was associated with an improvement in
cardiac function [26]. In extratumoral small vessels a
close correlation between VEGFR-1 and PlGF was docu-
mented, with significantly more non-metastatic than
metastatic cases revealing PlGF/VEGFR-1 co-expression.
Thus, an active autocrine PlGF/VEGFR-1 link in the
macrovasculature adjacent to the tumor seems to exist
in CC, which could protect against metastasis. It is
known that PlGF also has arteriogenic properties by in-
ducing the formation of large, stable blood vessels and
medium-size collaterals after ischemia [27,28]. Whether
the PlGF expression in the large and small vessels in our
study represents an arteriogenic potential of this factor
can only be speculated on at present. In one of our pre-
viously reported studies on the same cohort a third of
the investigated CC showed altered vessels with a dis-
continuous, hypoplastic muscle wall layer, which could
reflect immature tumor vascular entities possibly in the
course of arteriogenesis [16]. Interestingly, almost all of
them were PlGF-positive.
Recently, we reported that VEGF-B might also be an
important factor in ensuring a functional blood supply
for tumor survival in the absence of capillary participa-
tion [29]. In the present study these observations could
be confirmed, since there was only a macrovascular but
no capillary VEGF-B-expression. It is known that VEGF-
B promotes fatty acid transport across the endothelium
and lipid transport into tissues with an elevated rate of
cellular metabolism [14]. In our study the autochthon-
ous large and small vessels of the extratumoral tissue
expressed VEGF-B significantly more frequently in
distant-metastatic carcinomas. A possible explanation
for this finding could be an increased fatty acid transpor-
tation from the subserosal adipose tissue to the tumortissue, which had typically a low intratumoral small ves-
sel density and abundant tumor necroses [16]. In the
lymphogenous-metastatic carcinomas intratumoral VEGF-
B-positive small vessels were present in a significantly re-
duced number of cases. This tumor tissue was previously
characterized by a high extratumoral large vessel density
and relatively sparse tumor necrosis. It is probable that the
tumor center in these carcinomas has a sufficient blood
supply and consequently requires reduced lipid uptake.
We suppose that VEGF-B could fulfil a balancing regula-
tory function in lipid transport between energy-consuming
and energy-providing segments of the colonic tumor tissue.
In our study, PlGF was significantly overexpressed in
tumor cells of non-metastatic tumors in comparison
with distant metastatic cases. Escudero-Esparza et al. re-
ported similar results in CC at RNA-level with high ex-
pression in the earliest stages and remarkably low levels
in the presence of distant metastases [30]. These findings
point to a possible preventive role of PlGF secreted by
the tumor cells themselves in CC. In this context, PlGF-
overexpressing human colon tumor cells growing ortho-
topically in mice, inhibited angiogenesis, growth and
metastasis by an increase of PlGF homodimers and
PlGF/VEGF heterodimers [31]. In another experimental
study, tumor cells expressing the heterodimeric form of
PlGF/VEGF were found to be functionally inactive and
lacked the ability to induce angiogenesis in vitro and
in vivo [32]. It has also been reported that synthesis of
both factors VEGF and PlGF in the same cell may gen-
erate PlGF/VEGF heterodimer forms [13]. In the
present study autocrine formation of PlGF/PlGF homo-
dimers and PlGF/VEGF heterodimers by tumor cells
was about 88% in each comparative group. Concur-
rently, tumoral VEGFR-1 and pVEGFR-1Tyr1048 as well
as pVEGFR-1Tyr1213 expression and co-expression was
significantly correlated with distant metastasis. Thus,
the detected metastasis-preventing role of PlGF could
at least in part be due to receptor activation by PlGF
dimers, having a negative effect on distant organ
spread. However, since other in situ and experimental
studies found a PlGF-stimulated, enhanced metastatic
phenotype in cancer cells, additional analyses are
clearly needed for a further understanding of the com-
plex role of tumoral PlGF-expression [33-36].
VEGF-B positive cancer cells were detected only in
25% of the tumors, but significantly more frequently in
cases with distant metastasis. In vitro studies demon-
strated that VEGF-B led to significant induction of cell
motility and invasiveness of colon carcinoma cell lines
and epithelial to mesenchymal transition (EMT) in pan-
creatic carcinoma cell lines [37,38]. Tumor budding is
thought to reflect the biological process of EMT as a
manifestation of increased invasiveness [39]. Notably,
the presently documented VEGF-B expression in distant
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the cases with high tumor budding, while almost all
VEGF-B positive N0/M0- and N + −CC displayed low
tumor budding. Additionally, in the tumor budding re-
gions the correlation between VEGF-B immunopositivity
and distant metastasis was just below statistical signifi-
cance. These observations suggest a synergistic auxiliary
effect of VEGF-B in conjunction with high tumor bud-
ding for processes promoting distant CC metastasis.
The effects of VEGF are partly, and in the case of PlGF
and VEGF-B exclusively, mediated by the receptor
VEGFR-1 through receptor tyrosine phosphorylation,
which subsequently leads to activation of the major
downstream signaling pathways. In accordance with pre-
vious findings of our group in colorectal carcinomas,
lack of total VEGFR-1 in colonic tumor cells was signifi-
cantly associated with lymphogenous CC metastasis
[40]. In the current study, absence of tumoral pVEGFR-
1Tyr1048 and pVEGFR-1Tyr1213 expression as well as
VEGFR-1/pVEGFR-1 co-expression in the tumor center
was observed in cases with distant metastasis. Moreover,
in tumor budding regions lack of VEGFR-1/pVEGFR-1
co-expression was associated with haematogenous and
lymphogenous metastasis. These data indicate that
VEGFR-1 autophosphorylation at Tyr1048 or Tyr1213 is
acting as a negative regulatory mechanism for processes
facilitating CC metastasis. Because of the identical direc-
tional association of PlGF overexpression with the meta-
static status and the close correlation between PlGF and
VEGFR-1 expression, we assume that this ligand could
be a potential link of an autocrine loop having a protect-
ive effect in colon carcinoma cells themselves. To the
best of our knowledge other detailed data about the ex-
pression pattern of pVEGFR-1 in situ for CC and gener-
ally for malignant tumors are not yet to be found in the
literature. Our results concerning the correlation be-
tween VEGFR-1 downregulation and CC metastasis are
in accordance with those of Hanrahan et al., who found
significantly increased VEGFR-1 levels in CC without
metastasis in comparison with nodal-positive cases [17].
Furthermore, Garouniatis et al. concluded from their
studies that loss of VEGFR-1 predict distant metastasis
in CC [41]. In contrast, Wei et al. reported that PlGF ex-
pression correlates with VEGFR-1 expression, and high
m-RNA levels of both are associated with CC progres-
sion [33]. In the light of these contrasting findings a de-
tailed analysis with regard to the different cellular
components expressing this receptor could be insightful.
VEGFR-1, pVEGFR-1Tyr1048 and pVEGFR-1Tyr1213 were
also found in blood vessels of all vascular segments, but
only the macro vessels displayed significant differences
between the comparative tumor fractions. Thus, signifi-
cantly more non-metastatic CC revealed VEGFR-1/
pVEGFR-1 co-expression in small vessels in the tumorcenter or along the invasive front. This suggests that
VEGFR-1 activation of the tumor-associated branched
vascular network protects against CC metastasis.
Whether this is related to a regulation of tumoral hyp-
oxic conditions cannot be assessed at this time. Vascular
pVEGFR-1Tyr1333 expression seems to play a negligible
role. Interestingly, all cases with tumor-cell associated
positivity showed a nuclear expression of pVEGFR-
1Tyr1333. It is known that receptor tyrosine kinases are
also transported to the nucleus, where they may directly
impact nuclear signaling [42]. Ancillary molecular stud-
ies are necessary to verify the status of the phosphory-
lated receptor location in the cellular compartments.
Our study had several limitations, including a
relatively small number of investigated cases and the
exclusive use of immunohistochemistry as detection
method, although the detection of phosphorylated
moieties does yield some functional data. Thus, up to
now our study represents the first cohort to be investi-
gated in such detail and the present data enable an
initial assessment of the role of the VEGFR-1 pathway
for colon cancer metastasis. In this respect a major ad-
vantage of the immunohistochemical detection method
is the precise identification of both tumoral and non-
tumoral histological structures and their topological
distribution.Conclusion
Collectively, our study indicates that the total and phos-
phorylated VEGFR-1 and its ligands participate in vascular,
tumor cell-mediated and immuno-inflammatory processes
in a biomolecule-specific and tumor zone-specific manner
to prevent or to promote metastasis in CC. Figure 5 sum-
marizes these complex mechanisms of the VEGFR-1 acti-
vating pathway in CC tissue. PlGF-mediated autocrine
VEGFR-1 activation in tumor cells and paracrine receptor
activation in small vessels within the tumor and along the
invasive margin seem to have an inhibitory effect on me-
tastasis. PlGF/VEGFR-1 co-expression in extratumoral
small vessels and receptor expression in inflammatory cells
at the invasive front appear to be associated with a non-
metastatic phenotype. VEGF-B expression in tumor cells
and extratumoral macrovasculature is strongly associated
with metastasis. In contrast, VEGF-B-expressing small ves-
sels in the tumor center could possibly reduce the meta-
static potential of CC.
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